MediciNova Inc
MNOV1.430USD
-0.020-1.38%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
70.14MMarket Cap
LossP/E TTM
More Details of MediciNova Inc Company
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
MediciNova Inc Info
Ticker SymbolMNOV
Company nameMediciNova Inc
IPO dateDec 01, 2006
CEOIwaki (Yuichi)
Number of employees13
Security typeOrdinary Share
Fiscal year-endDec 01
Address4275 Executive Square
CityLA JOLLA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92037
Phone18583731500
Websitehttps://medicinova.com/
Ticker SymbolMNOV
IPO dateDec 01, 2006
CEOIwaki (Yuichi)
Company Executives of MediciNova Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
323.00K
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Mr. Jason J. Kruger
Mr. Jason J. Kruger
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
323.00K
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
134.60K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
3D Investment Partners Pte. Ltd
11.22%
EW Healthcare Partners
2.25%
Iwaki (Yuichi)
2.23%
The Vanguard Group, Inc.
1.43%
BlackRock Institutional Trust Company, N.A.
1.41%
Other
81.47%
Shareholders
Shareholders
Proportion
3D Investment Partners Pte. Ltd
11.22%
EW Healthcare Partners
2.25%
Iwaki (Yuichi)
2.23%
The Vanguard Group, Inc.
1.43%
BlackRock Institutional Trust Company, N.A.
1.41%
Other
81.47%
Shareholder Types
Shareholders
Proportion
Investment Advisor
15.16%
Individual Investor
2.88%
Venture Capital
2.25%
Investment Advisor/Hedge Fund
2.06%
Research Firm
1.67%
Hedge Fund
0.62%
Other
75.35%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
63
10.72M
21.85%
-557.99K
2025Q2
68
12.18M
24.84%
-512.65K
2025Q1
73
12.20M
24.88%
-318.34K
2024Q4
74
12.23M
24.94%
+65.83K
2024Q3
73
11.92M
24.31%
+15.81K
2024Q2
76
11.78M
24.02%
-90.59K
2024Q1
75
11.47M
23.39%
-882.87K
2023Q4
77
11.84M
24.14%
-895.64K
2023Q3
90
12.02M
24.50%
-1.28M
2023Q2
106
12.39M
25.26%
-1.32M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
3D Investment Partners Pte. Ltd
5.50M
11.22%
--
--
Aug 11, 2025
EW Healthcare Partners
1.11M
2.25%
--
--
Jun 30, 2025
Iwaki (Yuichi)
1.09M
2.23%
--
--
Aug 11, 2025
The Vanguard Group, Inc.
686.58K
1.4%
+63.00K
+10.10%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
686.58K
1.4%
-4.63K
-0.67%
Jun 30, 2025
Citi Investment Research (US)
591.96K
1.21%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
525.89K
1.07%
-1.11K
-0.21%
Jun 30, 2025
Matsuda (Kazuko)
323.00K
0.66%
--
--
Aug 11, 2025
UBS Financial Services, Inc.
222.20K
0.45%
--
--
Jun 30, 2025
Renaissance Technologies LLC
178.70K
0.36%
-3.00K
-1.65%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Dimensional US Core Equity 1 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of MediciNova Inc?
The top five shareholders of MediciNova Inc are:
3D Investment Partners Pte. Ltd holds 5.50M shares, accounting for 11.22% of the total shares.
EW Healthcare Partners holds 1.11M shares, accounting for 2.25% of the total shares.
Iwaki (Yuichi) holds 1.09M shares, accounting for 2.23% of the total shares.
The Vanguard Group, Inc. holds 686.58K shares, accounting for 1.40% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 686.58K shares, accounting for 1.40% of the total shares.
3D Investment Partners Pte. Ltd holds 5.50M shares, accounting for 11.22% of the total shares.
EW Healthcare Partners holds 1.11M shares, accounting for 2.25% of the total shares.
Iwaki (Yuichi) holds 1.09M shares, accounting for 2.23% of the total shares.
The Vanguard Group, Inc. holds 686.58K shares, accounting for 1.40% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 686.58K shares, accounting for 1.40% of the total shares.
What are the top three shareholder types of MediciNova Inc?
The top three shareholder types of MediciNova Inc are:
3D Investment Partners Pte. Ltd
EW Healthcare Partners
Iwaki (Yuichi)
3D Investment Partners Pte. Ltd
EW Healthcare Partners
Iwaki (Yuichi)
How many institutions hold shares of MediciNova Inc (MNOV)?
As of 2025Q3, 63 institutions hold shares of MediciNova Inc, with a combined market value of approximately 10.72M, accounting for 21.85% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.99%.
What is the biggest source of revenue for MediciNova Inc?
In FY2025Q2, the -- business generated the highest revenue for MediciNova Inc, amounting to -- and accounting for --% of total revenue.
